Published: 2021-04-22

Demographic profile, staging and CA-125 levels in a patient with pelvic lesions of probable ovarian origin at presentation in a tertiary care hospital

Rajeev Gupta, Shveta Mahajan, Sharandeep Kaur, Ankush Bansal, Dinesh Kumar, Jasneet Kaur Sodhi


Background: In Indian women, ovarian cancer is one of the most commonly diagnosed cancer. We wanted to analyze the demographic profile, staging, and sensitivity and specificity of CA-125 levels in a patient with ovarian cancer in an indian scenario.

Methods: A retrospective study was performed and information was collected from 250 patients who visited SGRD Hospital, Vallah, Amritsar from 1 April 2016 to 30 April 2020, with pelvic lesions of probable ovarian origin on demographic profile, the staging of the disease and CA-125 levels. Data was collected, analyzed, and presented in frequency tables and figures.

Results: The study comprised of 250 patients. CA-125 was mainly used to investigate a wide range of signs and symptoms and few tests were for follow up or screening of ovarian cancer. In female patients having a CA-125 for very high suspicion of malignancy/ovarian cancer, only 90 (36%) of the abnormal results were caused by ovarian cancer. False-positive results were largely caused by other malignancies. The specificity of CA-125 for ovarian cancer increased with concentrations over 1000 kU/litre. Serous adenocarcinoma was found the most common malignant tumor type of the ovary (53%). In the demographic profile, ovarian cancer was found to be highest in the sikh religious group (75%) and prevalent in the middle socioeconomic status 32% (n=80).

Conclusions: These results confirm the high false-positive rate and poor sensitivity and specificity associated with CA-125 and the most common tumor type. The substantial inappropriate usage of CA-125 has led to results that are useless to the clinician, have cost implications, and add to patient anxiety and clinical uncertainty.


Ovarian cancer, CA-125, Retrospective study

Full Text:



Tortolerol-Luna G, Mitchell FM, Rhodes-Morris HE. Epidemiology and screening of ovarian cancer. Obstet Gynecol Clin North Am. 1994;21(1):1-23.

Agarwal P, Kulkarni DG, Chakrabarti PR, Chourasia S, Dixit M, Gupta K. Clinicopathological spectrum of ovarian tumors: a 5-year experiencein a tertiary health care center. J Basic Clinic Reprod Sci. 2015;4(2):90-6.

Benson RC. In: DeCherney AH, Nathan L, Laufer N, Roman AS, eds. Diagnosis and Treatment. Current obstetrics gynaecol. 12th ed. New York, NY: McGraw-Hill: 1976.

Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem Suppl. 1995; 23:200-7.

Mondal SK, Banyopadhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: A 10-year study in a tertiary hospital of eastern India. J Can Res Ther. 2011;7(4):433-7.

Scully RE, Young RH, Clement PB. Tumors of ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas Tumor Path. 1999;189(1):145.

SEER*Stat Database: NAACCR Incidence Data - CiNA Analytic File, 1995–2014, for Expanded Races, Custom File With County, ACS Facts and Figures projection Project (which includes data from CDC’s National Program of Cancer Registries (NPCR), CCCR’s Provincial and Territorial Registries, and the NCI’s Surveillance, Epidemiology and End Results (SEER) Registries), certified by the North American Association of Central Cancer Registries (NAACCR) as meeting high-quality incidence data standards for the specified time periods, submitted December 2016.

Bast RC, Klug TL, John E, Jenison E, Niloff JM, Lazarus H et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883-7.

Crombach G, Zippel HH, Würz H. Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors. Geburtshilfe Frauenheilkd. 1985;45(4):205-12.

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267-77.

Cuesta R, Maestro ML, Solana J, Vidart JA, Escudero M, Iglesias E et al. Tissue quantification of CA 125 in epithelial ovarian cancer. Int J Biol Markers. 1999;14(2):106-14.

Kang WD, Choi HS, Kim SM. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Gynecol Oncol. 2010;116(1):57-60.

Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol. 2008:199(3):215-23.

Rev. Bras. Ginecol. Obstet. vol.27 no.4 Rio de Janeiro Apr. 2005. Available at:

Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A et al. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol. 2011;32(4):831-8.

Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gyecol Oncol. 2002;87(1):77-83.

Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6.

Derchain MSF, Franco ED, Sarian LO. Current situation and new perspectives on the early diagnosis of ovarian cancer. Rev Bras Ginecol Obstet. 2009;31(4):159-66.

Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ. Improved survival time: what can survival cure models tell us about population-based survival improvements in latestage colorectal, ovarian, and testicular cancer? Cancer. 2008;112(10):2289-300.

Reis FJC. Rastreamento e diagnóstico das neoplasias de ovário: papel dos marcadores tumorais. Rev Bras Ginecol Obstet. 2005;27(4):222-7.

Goldblum J, Lamps L, McKenney J, Myers J. Ovarian carcinoma-overview. In: Rosai J ed. Rosai and Ackerman’s Surgical Pathology. 11th ed. New York, NY: Elsevier; 2004: 1674-81.

Ryu SY, Park SI, Nam BH, Kim I, Yoo CW, Nam JH et al. Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol. 2009;20(6):1032-6.

Sankaranarayanan , R.; Ferlay , J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynecol. 2006;20(2):207-25.

Tavassoli FA, DeVilee P. Tumors of the ovary and peritoneum.In: WHO Classification of Tumors. Pathology and genetics of tumors of the breast and female genital tract. Breast Canc Res. 2003;6:117-92.

Alonso BC, Lario CC, Gomez JAF, Galve IA. Una lesión infrecuente en edad pediátrica: el cistoade94noma mucinoso de ovario. Ann Pediatr. 2005;62(4):385-6.

Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97(10):2631-42.

Chu CS, Rubin SC. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gyneco. 2006;20(2):307-20.

Alcázar JL, Errasti T, Zornoza A, Mínguez JA, Galán MJ. Transvaginal color Doppler ultrasonography and CA125 in suspicious adnexal masses. Int J Gynaecol Obstet. 1999;66(3):255-61.

Troiano RN, Quedens-Case C, Taylor KJ. Correlation of findings on transvaginal sonography with serum CA125 levels. AJR Am J Roentgenol. 1997;168(6):1587-90.

Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I et al. Combination of multiple serum markers using artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol. 1999;73(1):56-61.

Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (C125, CA15-3, and CA72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol. 2002;187:385-92.

Sjovall K, Nilsson B, Einhorn N. The significance of serum CA125 elevation in malignant and non-malignant diseases. Gynecol Oncol. 2002;85(1):175-8.

Eltabbakh GH, Belinson JL, Kennedy AW, Gupta M, Webster K, Blumenson LE. Serum CA125 measurements .65 U/mL. Clinical value. J Reprod Med. 1997;42(10):617-24.

Kammerer-Doak DN, Magrina JF, Nemiro JS, Lidner TK. Benign gynaecologic conditions associated with a CA-125 level .1,000 U/mL. A case report. J Reprod Med. 1996;41(3):179-82.

Daoud E, Bodor G. CA-125 concentrations in malignant and non-malignant disease. Clin Chem. 1991;37(11):1968-74.